Cote d'Ivoire

Publication Title: 
The American Journal of Tropical Medicine and Hygiene

Artemether is an efficacious antimalarial drug that also displays antischistosomal properties. Laboratory studies have found that artemether curtails the development of adult worms of Schistosoma japonicum, S. mansoni and S. haematobium, and thus prevents morbidity. These findings have been confirmed in clinical trials for the former two parasites; administered orally once every 2-3 weeks, artemether significantly reduced the incidence and intensity of patent infections. Here, we present the first randomized, double-blind, placebo-controlled trial of artemether against S.

Author(s): 
N'Goran, Eliézer K.
Utzinger, Jürg
Gnaka, Henri N.
Yapi, Ahoa
N'Guessan, Nicaise A.
Kigbafori, Silué D.
Lengeler, Christian
Chollet, Jacques
Shuhua, Xiao
Tanner, Marcel
Publication Title: 
Malaria Journal

BACKGROUND: Artemisinin-containing therapies are highly effective against Plasmodium falciparum malaria. Insufficient numbers of tablets and inadequate package inserts result in sub-optimal dosing and possible treatment failure. This study reports the case of three, non-immune, expatriate workers with P. falciparum acquired in Africa, who failed to respond to artemisinin-based therapy. Sub-therapeutic dosing in accordance with the manufacturers' recommendations was the probable cause.

Author(s): 
Jackson, Yves
Chappuis, François
Loutan, Louis
Taylor, Walter
Publication Title: 
International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases

OBJECTIVES: Malaria kills approximately 1.5 to 2.7 million people each year. Despite the introduction of artemisinin-based combination therapies (ACTs), the treatment of malaria is hampered by problems such as inadequate efficacy, recrudescence, early re-infection, low patient compliance, and high cost price of drugs.

Author(s): 
Penali, Louis Koné
Jansen, Frans Herwig
Publication Title: 
Malaria Journal

BACKGROUND: Drug resistance in Plasmodium falciparum poses a major threat to malaria control. Combination anti-malarial therapy, including artemisinins, has been advocated to improve efficacy and limit the spread of resistance. The fixed combination of oral artemether-lumefantrine (AL) is highly effective and well-tolerated. Artemisinin/naphtoquine (AN) is a fixed-dose ACT that has recently become available in Africa.

Author(s): 
Toure, Offianan A.
Pénali, Louis K.
Yapi, Jean-Didier
Ako, Berenger A.
Toure, Walamtchin
Djerea, Kali
Gomez, Genevieve O.
Makaila, Oyewole
Publication Title: 
Tropical medicine & international health: TM & IH

OBJECTIVE: To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet to artemether-lumefantrine (Coartem) for the treatment of Plasmodium falciparum uncomplicated malaria in Ivory Coast and Senegal. METHOD: Multisite, randomised, open-labelled study in patients over the age of 7 years. The primary endpoint for efficacy was adequate clinical and parasitological response (ACPR) at day 28. The secondary endpoints were fever and parasite clearance and gametocyte carriage in each treatment group.

Author(s): 
Faye, Babacar
Offianan, André Toure
Ndiaye, Jean Louis
Tine, Roger Clement
Touré, Walatchin
Djoman, Kali
Sylla, Khadime
Ndiaye, Paulette Suzanne
Penali, Louis
Gaye, Oumar
Publication Title: 
Malaria Journal

BACKGROUND: The ACT recommended by WHO is very effective and well-tolerated. However, these combinations need to be administered for three days, which may limit adherence to treatment.The combination of dihydroartemisinin-piperaquine phosphate-trimethoprim (Artecom®, Odypharm Ltd), which involves treatment over two days, appears to be a good alternative, particularly in malaria-endemic areas.

Author(s): 
Menan, Hervé
Faye, Oumar
Same-Ekobo, Albert
Oga, Agbaya Serge S.
Faye, Babacar
Kiki Barro, Christiane P.
Kuété, Thomas
N'diaye, Jean-Louis
Vicky, Ama-Moor
Tine, Rogert
Yavo, William
Kane, Dieynaba
Kassi, Kondo F.
Koné, Moussa
Publication Title: 
Malaria Journal

BACKGROUND: The choice of appropriate artemisinin-based combination therapy depends on several factors (cost, efficacy, safety, reinfection rate and simplicity of administration). To assess whether the combination dihydroartemisinin-piperaquine (DP) could be an alternative to artemether-lumefantrine (AL), the efficacy and the tolerability of the two products for the treatment of uncomplicated falciparum malaria in sub-Saharan Africa have been compared.

Author(s): 
Yavo, William
Faye, Babacar
Kuété, Thomas
Djohan, Vincent
Oga, Serge A.
Kassi, Richard R.
Diatta, Mariama
Ama, Moor V.
Tine, Roger
Ndiaye, Jean-Louis
Evi, Jean-Bedel
Same-Ekobo, Albert
Faye, Oumar
Koné, Moussa
Publication Title: 
Malaria Journal

BACKGROUND: This multicentre study was carried out in Cameroon, Ivory Coast and Senegal to evaluate the non-inferiority of the new paediatric formulation of artesunate/amodiaquine (AS+AQ)(Camoquin-Plus Paediatric®) in suspension form versus artemether/lumefantrine (AL)(Coartem®) in the management of African children with uncomplicated falciparum malaria. METHODS: It was an open randomized trial including children aged between 7 months and 7 years. The endpoints were Adequate Clinical and Parasitological Response (ACPR) at day 28, the clinical and biological tolerability.

Author(s): 
Faye, Babacar
Kuété, Thomas
Kiki-Barro, Christiane P.
Tine, Roger C.
Nkoa, Thérèse
Ndiaye, Jean Louis A.
Kakpo, Claude A.
Sylla, Khadime
El Menan, Hervé
Gaye, Oumar
Faye, Oumar
Same-Ekobo, Albert
Moussa, Koné
Publication Title: 
Malaria Journal

BACKGROUND: Parenteral artesunate is recommended as first-line therapy for severe and complicated malaria. Although its efficacy has been proven, long-term safety profile is still under evaluation. Several cases of delayed haemolytic anaemia occurred after initial clinical improvement and resolution of parasitaemia in non-immune travellers and children living in endemic areas. Reports have generated concern that this phenomenon might be related to the treatment itself, either by direct toxicity or immune-related mechanism.

Author(s): 
Raffray, Loic
Receveur, Marie-Catherine
Beguet, Mathilde
Lauroua, Pierre
Pistone, Thierry
Malvy, Denis
Publication Title: 
Malaria Journal

BACKGROUND: Emergence of artemisinin resistance has raised concerns that the most potent anti-malarial drug may be under threat. Artesunate-amodiaquine (AS-AQ) and artemether-lumefantrine (AL) are, respectively, the first- and second-line treatments for uncomplicated falciparum malaria in Côte d'Ivoire. Constant monitoring by National Malaria Control Programme (NMCP) of drug efficacy is an important tool in establishing rational anti-malarial drug policies in Côte d'Ivoire.

Author(s): 
Toure, Offianan A.
Assi, Serge B.
N'Guessan, Tiacoh L.
Adji, Gbessi E.
Ako, Aristide B.
Brou, Marie J.
Ehouman, Marie F.
Gnamien, Laeticia A.
Coulibaly, M'Lanhoro A. A.
Coulibaly, Baba
Beourou, Sylvain
Bassinka, Issiaka
Soumahoro, Adama
Kadjo, Florence
Tano, Mea A.

Pages

Subscribe to RSS - Cote d'Ivoire